Science

Pipeline
Program
Target
Indication
Mono/Combo
Discovery
IND Enabling
Phase I/Ia
POC
Pivotal
Rights
Partner
Precision Oncology
ABSK011*
FGFR4
FGF19+ HCC
Monotherapy
Global
ABSK011*
FGFR4
FGF19+ HCC
Combination
therapy(ⅱ)
Global
ABSK012
FGFR4 Mutant
RMS and other
solid tumors
Monotherapy
Global
ABSK091*
pan-FGFR
FGFRalt UC
Monotherapy
global
Global
AstraZeneca
ABSK091*
pan-FGFR
FGFRalt UC
Combination therapy
Global
AstraZeneca
ABSK091*
pan-FGFR
FGFRalt GC
Monotherapy/ Combination therapy
global
Global
AstraZeneca
ABSK091*
pan-FGFR
Other solid tumors
Monotherapy/ Combination therapy
Global
AstraZeneca
ABSK061
FGFR2/3
Solid tumors
Monotherapy
Global
ABSK121
pan-FGFR Mutant
Solid tumors
Monotherapy
Global
ABSK071
KRAS
Solid tumors
Monotherapy
Global
ABSK111
EGFR Exon20
NSCLC
Monotherapy
Global
ABSK131
Undisclosed
Multiple tumors
Monotherapy
Global
ABSK141
Undisclosed
Multiple tumors
Monotherapy
Global
Immuno-Oncology
ABSK021
CSF-1R
TGCT, solid tumors
Monotherapy
Global
ABSK021
CSF-1R
Solid tumors
Combination therapy
Global
ABSK021
CSF-1R
cGvHD
Monotherapy
Global
ABSK021
CSF-1R
ALS
Monotherapy
Global
ABSK081
CXCR4
TNBC
Combination therapy(ⅲ)
Greater China
X4
ABSK081
CXCR4
Other solid tumors
Combination therapy
Greater China
X4
ABSK081
CXCR4
WHIM
Monotherapy
global
Greater China
X4
ABSK043
PD-L1
Multiple tumors
Monotherapy
Global
ABSK051
CD73
Multiple tumors
Monotherapy
Global
ABSK031
RORγt
Multiple tumors
Monotherapy
Global

Tel:(+86) 021-68912098

E-MailL:Public@abbisko.com Bd@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     滬ICP備17056565號-1